GlaxoSmithKline
GSK
$37.43
Share price
-0.51%
Change (1 day)
-8.30%
Change (1 year)
Categories
GlaxoSmithKline (GSK) - Cash on Hand
Cash on Hand as of June 2023 : $8.20 B
According to GlaxoSmithKline's latest financial reports the company has $8.20 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
GlaxoSmithKline - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2022-12-31 | $9.54 B | 63.16% |
| 2021-12-31 | $5.85 B | -32.61% |
| 2020-12-31 | $8.68 B | 38.35% |
| 2019-12-31 | $6.27 B | 24.92% |
| 2018-12-31 | $5.02 B | -4.96% |
| 2017-12-31 | $5.28 B | -14.15% |
| 2016-12-31 | $6.15 B | -29.64% |
| 2015-12-31 | $8.75 B | 27.54% |
| 2014-12-31 | $6.86 B | -25.72% |
| 2013-12-31 | $9.23 B | 34% |
| 2012-12-31 | $6.89 B | -24.65% |
| 2011-12-31 | $9.14 B | -6.43% |
| 2010-12-31 | $9.77 B | -12.96% |
| 2009-12-31 | $11.23 B | 36.31% |
| 2008-12-31 | $8.24 B | -8.47% |
| 2007-12-31 | $9.00 B | 50.78% |
| 2006-12-31 | $5.97 B | -33.64% |
| 2005-12-31 | $8.99 B | 17.8% |
| 2004-12-31 | $7.63 B | 18% |
| 2003-12-31 | $6.47 B | 106.72% |
| 2002-12-31 | $3.13 B | 6.36% |
| 2001-12-31 | $2.94 B |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $11.17 B | 36.19% | 🇨🇭 Switzerland |
 Pfizer PFE | $19.97 B | 143.43% | 🇺🇸 USA |
 Sanofi SNY | $8.68 B | 5.88% | 🇫🇷 France |
 Merck MRK | $10.38 B | 26.60% | 🇺🇸 USA |
 AstraZeneca AZN | $5.81 B | -29.16% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $2.66 B | -67.47% | 🇮🇱 Israel |
 Dynavax Technologies
DVAX | $0.68 B | -91.69% | 🇺🇸 USA |